[go: up one dir, main page]

WO2013040564A2 - Anticorps reconnaissant un épitope conçu arbitrairement d'au moins trois résidus d'acides aminés dans un peptide, et procédé de génération de celui-ci - Google Patents

Anticorps reconnaissant un épitope conçu arbitrairement d'au moins trois résidus d'acides aminés dans un peptide, et procédé de génération de celui-ci Download PDF

Info

Publication number
WO2013040564A2
WO2013040564A2 PCT/US2012/055771 US2012055771W WO2013040564A2 WO 2013040564 A2 WO2013040564 A2 WO 2013040564A2 US 2012055771 W US2012055771 W US 2012055771W WO 2013040564 A2 WO2013040564 A2 WO 2013040564A2
Authority
WO
WIPO (PCT)
Prior art keywords
amino acid
acid residues
peptide
antibody
peptide vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2012/055771
Other languages
English (en)
Other versions
WO2013040564A3 (fr
Inventor
Zhiwei WU
Xilin WU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing University
Nanjing Tech University
Original Assignee
Nanjing University
Nanjing Tech University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing University, Nanjing Tech University filed Critical Nanjing University
Priority to HK15101049.2A priority Critical patent/HK1200359A1/xx
Priority to JP2014530928A priority patent/JP2014527085A/ja
Priority to EP12832007.4A priority patent/EP2755687A4/fr
Priority to CN201280045106.2A priority patent/CN104039350B/zh
Priority to AU2012308212A priority patent/AU2012308212A1/en
Priority to CA2855781A priority patent/CA2855781A1/fr
Publication of WO2013040564A2 publication Critical patent/WO2013040564A2/fr
Publication of WO2013040564A3 publication Critical patent/WO2013040564A3/fr
Anticipated expiration legal-status Critical
Priority to AU2017251715A priority patent/AU2017251715A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne un vaccin peptidique qui est un mélange de différentes espèces peptidiques, chaque espèce ayant un nombre de résidus d'acides aminés fixes et un nombre de résidus aléatoires. Les résidus fixes sont les mêmes résidus d'acides aminés aux positions correspondantes dans chaque espèce du mélange, alors que les résidus aléatoires sont aléatoirement tout acide aminé candidat disponible choisi à dessein. Le degré de randomisation peut être également choisi selon la conception dans une situation particulière. Ce type de vaccin peptidique s'est avéré être apte à induire des anticorps extrêmement spécifiques, dirigés contre des épitopes qui sont autrement difficiles pour induire des anticorps in vitro, par exemple le triplet GPG dans le V3 de glp20 de VIH-1.
PCT/US2012/055771 2011-09-17 2012-09-17 Anticorps reconnaissant un épitope conçu arbitrairement d'au moins trois résidus d'acides aminés dans un peptide, et procédé de génération de celui-ci Ceased WO2013040564A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
HK15101049.2A HK1200359A1 (en) 2011-09-17 2012-09-17 Antibody recognizing arbitrarily designed epitope of three or more amino acid residues in a peptide and method of generating thereof
JP2014530928A JP2014527085A (ja) 2011-09-17 2012-09-17 ペプチドにおける３個以上のアミノ酸残基の任意に設計されたエピトープを認識する抗体およびその生成方法
EP12832007.4A EP2755687A4 (fr) 2011-09-17 2012-09-17 Anticorps reconnaissant un épitope conçu arbitrairement d'au moins trois résidus d'acides aminés dans un peptide, et procédé de génération de celui-ci
CN201280045106.2A CN104039350B (zh) 2011-09-17 2012-09-17 任意三个或以上氨基酸残基构成的多肽表位及其相关抗体的诱导
AU2012308212A AU2012308212A1 (en) 2011-09-17 2012-09-17 Antibody recognizing arbitrarily designed epitope of three or more amino acid residues in a peptide and method of generating thereof
CA2855781A CA2855781A1 (fr) 2011-09-17 2012-09-17 Anticorps reconnaissant un epitope concu arbitrairement d'au moins trois residus d'acides amines dans un peptide, et procede de generation de celui-ci
AU2017251715A AU2017251715A1 (en) 2011-09-17 2017-10-24 Antibody recognizing arbitrarily designed epitope of three or more amino acid residues in a peptide and method of generating thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161535988P 2011-09-17 2011-09-17
US61/535,988 2011-09-17

Publications (2)

Publication Number Publication Date
WO2013040564A2 true WO2013040564A2 (fr) 2013-03-21
WO2013040564A3 WO2013040564A3 (fr) 2013-06-27

Family

ID=47884023

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/055771 Ceased WO2013040564A2 (fr) 2011-09-17 2012-09-17 Anticorps reconnaissant un épitope conçu arbitrairement d'au moins trois résidus d'acides aminés dans un peptide, et procédé de génération de celui-ci

Country Status (7)

Country Link
EP (1) EP2755687A4 (fr)
JP (2) JP2014527085A (fr)
CN (1) CN104039350B (fr)
AU (2) AU2012308212A1 (fr)
CA (1) CA2855781A1 (fr)
HK (1) HK1200359A1 (fr)
WO (1) WO2013040564A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016062294A1 (fr) * 2014-10-24 2016-04-28 Versitech Limited Composés à motif d'adn et procédés pour induire des anticorps spécifiques et une immunité cellulaire

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111153996B (zh) * 2020-01-10 2021-12-14 苏州睿瀛生物技术有限公司 G蛋白偶联受体的抗体及其制备方法和g蛋白偶联受体试剂盒

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0725838A4 (fr) * 1993-10-26 1997-02-26 United Biomedical Inc Bibliotheques structurees d'antigenes de synthese utilisables a des fins de diagnostic, de vaccin et de therapie
WO1995011701A1 (fr) * 1993-10-26 1995-05-04 Syntello, Inc. Inhibition de l'infection des muqueuses par le vih
US6441140B1 (en) * 1998-09-04 2002-08-27 Cell Signaling Technology, Inc. Production of motif-specific and context-independent antibodies using peptide libraries as antigens
US9289487B2 (en) * 1999-09-14 2016-03-22 Antigen Express, Inc. II-key/antigenic epitope hybrid peptide vaccines
FR2809402A1 (fr) * 2000-05-26 2001-11-30 Dev Des Antigenes Combinatoire Bibliotheques peptidiques combinatoires convergentes et leur application a la vaccination contre le virus de l'hepatite c
AU2005211424A1 (en) * 2004-02-02 2005-08-18 Mixture Sciences, Inc. Peptide mixtures with immunomodulatory activity
EP2205736B1 (fr) * 2007-10-09 2014-04-02 Technologie Integrale Ltd. Méthode de préparation d'un composé immunogénique contre le VIH à base d'anticorps spécifiques pour HIV

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHALES-NINO ET AL., VACCINE, vol. 29, 2011, pages 5313 - 5321
KELLER ET AL., VIROLOGY, vol. 193, 1993, pages 709 - 716

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016062294A1 (fr) * 2014-10-24 2016-04-28 Versitech Limited Composés à motif d'adn et procédés pour induire des anticorps spécifiques et une immunité cellulaire
CN107208110A (zh) * 2014-10-24 2017-09-26 港大科桥有限公司 用于诱导特异性抗体和细胞免疫的dna基序化合物和方法
EP3209784A4 (fr) * 2014-10-24 2018-06-27 Versitech Limited Composés à motif d'adn et procédés pour induire des anticorps spécifiques et une immunité cellulaire
US10245313B2 (en) 2014-10-24 2019-04-02 Versitech Limited DNA motif compounds and methods for inducing specific antibodies and cellular immunity

Also Published As

Publication number Publication date
CA2855781A1 (fr) 2013-03-21
EP2755687A2 (fr) 2014-07-23
AU2017251715A1 (en) 2017-11-09
CN104039350A (zh) 2014-09-10
JP2017141291A (ja) 2017-08-17
HK1200359A1 (en) 2015-08-07
JP2014527085A (ja) 2014-10-09
EP2755687A4 (fr) 2015-04-08
CN104039350B (zh) 2019-07-05
WO2013040564A3 (fr) 2013-06-27
AU2012308212A1 (en) 2014-03-27

Similar Documents

Publication Publication Date Title
Selvarajah et al. Comparing antigenicity and immunogenicity of engineered gp120
CA2858347C (fr) Immunogenes v1v2
EP0570357A2 (fr) Peptides induisant des anticorps, qui neutralisent des isolées d'HIV-1 qui divergent génétiquement
Liu et al. The development of HIV vaccines targeting gp41 membrane-proximal external region (MPER): challenges and prospects
Qin et al. Eliciting neutralizing antibodies with gp120 outer domain constructs based on M-group consensus sequence
Choudhry et al. Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies
Pinter Roles of HIV-1 Env variable regions in viral neutralization and vaccine development
Zhang et al. Cross-reactive HIV-1-neutralizing activity of serum IgG from a rabbit immunized with gp41 fused to IgG1 Fc: possible role of the prolonged half-life of the immunogen
Haynes et al. Analysis of HIV-1 subtype B third variable region peptide motifs for induction of neutralizing antibodies against HIV-1 primary isolates
JPH05503851A (ja) 中和および／またはａｄｃｃ仲介モノクローナルｈｉｖ抗体
Visciano et al. In vivo alteration of humoral responses to HIV-1 envelope glycoprotein gp120 by antibodies to the CD4-binding site of gp120
Kumar et al. CD4-binding site directed cross-neutralizing scFv monoclonals from HIV-1 subtype C infected Indian children
AU2017251715A1 (en) Antibody recognizing arbitrarily designed epitope of three or more amino acid residues in a peptide and method of generating thereof
Humbert et al. Inducing cross-clade neutralizing antibodies against HIV-1 by immunofocusing
US20040241641A1 (en) Peptides mimicking a cryptic epitope of gp41 hiv-1
Gao et al. Cross-reactive monoclonal antibodies to multiple HIV-1 subtype and SIVcpz envelope glycoproteins
Cham et al. Neutralization and infectivity characteristics of envelope glycoproteins from human immunodeficiency virus type 1 infected donors whose sera exhibit broadly cross-reactive neutralizing activity
JPH0570493A (ja) ヒト免疫不全ウイルス（ｈｉｖ）関連免疫調製物
Ringel et al. Optimization of the EC26-2A4 epitope in the gp41 membrane proximal external region targeted by neutralizing antibodies from an elite controller
US10660951B2 (en) Antibody recognizing arbitrarily designed epitope of three or more amino acid residues in a peptide and method of generating thereof
AU2005223352B2 (en) Novel Tat complexes, and vaccines comprising them
Steimer et al. HIV-1 neutralization directed to epitopes other than linear V3 determinants
S Shcherbakova et al. Artificial polyepitope HIV-1 immunogen containing mimotope of 2F5 epitope
Ching et al. Alterations in the immunogenic properties of soluble trimeric human immunodeficiency virus type 1 envelope proteins induced by deletion or heterologous substitutions of the V1 loop
REEVES et al. Mouse monoclonal antibodies to human immunodeficiency virus glycoprotein 120 generated by repeated immunization with glycoprotein 120 from a single isolate, or by sequential immunization with glycoprotein 120 from three isolates

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12832007

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2014530928

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2855781

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2012308212

Country of ref document: AU

Date of ref document: 20120917

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2012832007

Country of ref document: EP